Citations

Showing 10 of 108162 citations.

Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
Eugene, Andy R., Liu, Duan , Zhang, Lingxin , Neavin, Drew , Yu, Jia , Weinshilboum, Richard M. , Wang, Liewei , Neavin, Drew R , Liu, Duan , Qin, Sisi , Eugene, Andy R., Biernacka, Joanna M. , Weinshilboum, Richard M.

Mayo Clinic

Clinical Pharmacology & Therapeutics | October 19, 2019 | Volume: 107 | Issue: 3 | Pages: 662-670

10.1002/cpt.1692 | PMID 31628858 Get It

We previously reported that testis‐specific Y‐encoded‐like protein (TSPYLs) are transcription regulators for CYP3A4, CYP2C9, and CYP2C19. Here, we observed dual roles for TSPYLs in mediating serotonin transport and the metabolism of selective serotonin reuptake inhibitors (SSRIs) in patients with major depressive disorder (MDD). The widely prescribed SSRIs, citalopram, and escitalopram are metabolized mainly by CYP2C19. The TSPYL1 rs3828743 single nucleotide polymorphism (SNP), which decreases its suppression of CYP2C19 expression, was associated with rapid escitalopram metabolism and worse treatment response in the Mayo PGRN‐AMPS clinical trial. We also found that TSPYLs can regulate expression of the serotonin transporter protein, SLC6A4, and, in turn, serotonin transport into cells. The SNPs in tight linkage disequilibrium with the TSPYL1 rs10223646 SNP were significantly correlated with baseline severity of depression in patients with MDD in the Sequenced Treatment Alternatives to Relieve Depression and International SSRI Pharmacogenomics Consortium clinical trials. Our findings suggest that genetic variation in TSPYL genes may be novel indicators for baseline severity of depression and SSRI poor response.
Gender of pain medicine leadership and trainees: a survey study
Pittelkow, Thomas P. , Furnish, Timothy , Brancolini, Scott, Schroeder, Darrell R. , Gazelka, Halena M. , Moeschler, Susan M. , Hagedorn, Jonathan Michael, Pittelkow, Thomas P , Warner, Nafisseh, Gazelka, Halena, Moeschler, Susan, Schroeder, Darrell , Hagedorn, Jonathan M. , Warner, Nafisseh S.

Mayo Clinic

Regional Anesthesia & Pain Medicine | October 19, 2019 | Volume: 44 | Issue: 12 | Pages: 1091-1093

10.1136/rapm-2019-100878 | PMID 31630134 Get It

Background Women are entering medical school in record numbers, but multiple male-dominated medical specialties still exist, including pain medicine. It is not well-understood how gender diversity in academic pain medicine faculty affects fellow matriculation between female and male applicants. Objective We conducted a survey to ascertain whether gender diversity of those in leadership roles in pain medicine programs impacts the gender diversity of fellows in those programs. Methods A questionnaire was delivered to all Accreditation Council for Graduate Medical Education-accredited pain medicine fellowships to assess their demographic data in 2018. Program characteristics are summarized using median (25th, 75th) for continuous variables and frequency counts and percentages for categorical variables. Analyses were then performed using a generalized linear mixed model with a logit link function and fellowship program included as a random effect. The gender of the fellow was the dependent variable and the program characteristics were the explanatory variables. Results Data from 45 of 104 fellowship programs (43% response rate) are included. From univariate analysis, the odds of a fellow being female were higher in programs with a female program director (OR=2.17, 95% CI 1.29 to 3.65, p=0.004) and in programs with a higher percentage of female faculty (OR=1.02, 95% CI 1.00 to 1.04, p=0.027). From multivariable analysis, having a female program director was the only program characteristic found to be significantly associated with female fellows (OR=2.07, 95% CI 1.05 to 4.11, p=0.037). Conclusions Pain medicine fellowship programs with a female program director were significantly more likely to have female fellows.
Teriparatide treatment increases Hounsfield units in the lumbar spine out of proportion to DEXA changes
Mikula, Anthony L. , Puffer, Ross C. , Jeor, Jeffery D. St. , Bernatz, James T. , Fogelson, Jeremy L. , Sebastian, Arjun S. , Freedman, Brett A. , Currier, Bradford L. , Bydon, Mohamad , Yaszemski, Michael J. , Anderson, Paul A. , Elder, Benjamin D. , Larson, A. Noelle , Nassr, Ahmad

Mayo Clinic

Journal of Neurosurgery: Spine | October 19, 2019 | Volume: 32 | Issue: 1 | Pages: 50-55

10.3171/2019.7.spine19654 | PMID 31628287 Get It

OBJECTIVEThe authors sought to assess whether Hounsfield units (HU) increase following teriparatide treatment and to compare HU increases with changes in bone mineral density (BMD) as measured by dual-energy x-ray absorptiometry (DEXA).METHODSA retrospective chart review was performed from 1997 to 2018 across all campuses at our institution. The authors identified patients who had been treated with at least 6 months of teriparatide and compared HU and BMD as measured on DEXA scans before and after treatment.RESULTSFifty-two patients were identified for analysis (46 women and 6 men, average age 67 years) who underwent an average of 20.9 ± 6.5 months of teriparatide therapy. The mean ± standard deviation HU increase throughout the lumbar spine (L1–4) was from 109.8 ± 53 to 133.9 ± 61 HU (+22%, 95% CI 1.2–46, p value = 0.039). Based on DEXA results, lumbar spine BMD increased from 0.85 to 0.93 g/cm2 (+9%, p value = 0.044). Lumbar spine T-scores improved from −2.4 ± 1.5 to −1.7 ± 1.5 (p value = 0.03). Average femoral neck T-scores improved from −2.5 ± 1.1 to −2.3 ± 1.0 (p value = 0.31).CONCLUSIONSTeriparatide treatment increased both HU and BMD on DEXA in the lumbar spine, without a change in femoral BMD. The 22% improvement in HU surpassed the 9% improvement determined with DEXA. These results support some surgeons’ subjective sense that intraoperative bone quality following teriparatide treatment is better than indicated by DEXA results. To the authors’ knowledge, this is the first study demonstrating an increase in HU with teriparatide treatment.
Exercise-induced hypoxemia predicts heart failure hospitalization and death in patients supported with left ventricular assist devices
Koerber, Daniel M. , Rosenbaum, Andrew , Olson, Thomas P. , Kushwaha, Sudhir S. , Stulak, John M., Maltais, Simon, Behfar, Atta , Rosenbaum, Andrew N , Kushwaha, Sudhir, Behfar, Atta

Mayo Clinic

The International Journal of Artificial Organs | October 19, 2019 | Volume: 43 | Issue: 3 | Pages: 165-172

10.1177/0391398819882435 | PMID 31630619 Get It

Following implantation of continuous-flow left ventricular assist devices, mechanical off-loading results in improved resting hemodynamics; however, peak exercise capacity generally does not increase substantially. This study evaluated patients supported by continuous-flow left ventricular assist devices who were invasively monitored during exercise to define parameters that underpin exercise capacity and outcomes. A review of all patients supported by continuous-flow left ventricular assist devices who underwent supine bicycle ergometry exercise testing with measurement of pulmonary gas exchange during right heart catheterization for evaluation of dyspnea at one institution between 2007 and 2018 was performed (n = 22). The primary outcome of this investigation was death or heart failure hospitalization. Although resting filling pressures were relatively preserved, resting cardiac index (Fick) was low (2.1 ± 0.5 mL/kg/min). An impaired cardiac output reserve was present in 75% of patients. On univariate modeling, patients with supine exercise–induced hypoxemia (O 2 saturation <90%) experienced significantly diminished hospitalization-free survival (unadjusted hazard ratio = 11.0, confidence interval = 2.4–57.2, p = 0.003), which persisted despite adjustment for right heart catheterization peak VO 2 and peak cardiac output (adjusted hazard ratio = 25, confidence interval = 3.6–322, p = 0.001). Our findings suggest that supine exercise testing provides additional prognostic utility in the continuous-flow left ventricular assist device population.
Pediatric ganglioglioma of the brainstem and cervicomedullary junction: a retrospective cohort study
Oushy, Soliman , Perry, Avital , Graffeo, Christopher S. , Oushy, Soliman H , Raghunathan, Aditya , Carlstrom, Lucas P. , Daniels, David J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | October 19, 2019 | Volume: 25 | Issue: 1 | Pages: 30-36

10.3171/2019.7.peds1961 | PMID 31585412 Get It

OBJECTIVEGanglioglioma is a low-grade central nervous system neoplasm with a pediatric predominance, accounting for 10% of all brain tumors in children. Gangliogliomas of the cervicomedullary junction (GGCMJs) and brainstem (GGBSs) present a host of management challenges, including a significant risk of surgical morbidity. At present, understanding of the prognostic factors—including BRAF V600E status—is incomplete. Here, the authors report a single-institution GGCMJ and GGBS experience and review the pertinent literature.METHODSA prospectively maintained neurosurgical database at a large tertiary care academic referral center was retrospectively queried for cases of GGCMJ pathologically confirmed in the period from 1995 to 2015; appropriate cases were defined by diagnosis codes and keywords. Secondary supplemental chart review was conducted to confirm or capture relevant data. The primary study outcome was treatment failure as defined by evidence of radiographic recurrence or progression and/or clinical or functional decline. A review of the literature was conducted as well.RESULTSFive neurosurgically managed GGBS patients were identified, and the neoplasms in 4 were classified as GGCMJ. All 5 patients were younger than 18 years old (median 15 years, range 4–16 years) and 3 (60%) were female. One patient underwent gross-total resection, 2 underwent aggressive subtotal resection (STR), and 2 underwent stereotactic biopsy only. All patients who had undergone STR or biopsy required repeat resection for tumor control or progression. Progressive disease was treated with radiotherapy in 2 patients, chemotherapy in 2, and chemoradiotherapy alone in 1. Immunostaining for BRAF V600E was positive in 3 patients (60%). All 5 patients experienced at least one major complication, including wound infection, foot drop, hemiparesis, quadriparesis, cranial neuropathy, C2–3 subluxation, syringomyelia, hydrocephalus, aspiration, and coma. Overall mortality was 20%, with 1 death observed over 11 years of follow-up.CONCLUSIONSGGBS and GGCMJ are rare, benign posterior fossa tumors that carry significant perioperative morbidity. Contemporary management strategies are heterogeneous and include combinations of resection, radiotherapy, and chemotherapy. The BRAF V600E mutation is frequently observed in GGBS and GGCMJ and appears to have both prognostic and therapeutic significance with targeted biological agents.
Radiological and clinical predictors of scoliosis in patients with Chiari malformation type I and spinal cord syrinx from the Park-Reeves Syringomyelia Research Consortium
Strahle, Jennifer M. , Taiwo, Rukayat , Averill, Christine, Torner, James C., Shannon, Chevis N. , Bonfield, Christopher M. , Tuite, Gerald F. , Bethel-Anderson, Tammy, Rutlin, Jerrel, Brockmeyer, Douglas L. , Wellons, John C. , Leonard, Jeffrey R. , Mangano, Francesco T. , Johnston, James M. , Iskandar, Bermans J. , Tyler‐Kabara, Elizabeth C. , Jackson, Eric M. , Couture, Daniel E., Adelson, P. David , Alden, Tord D. , Aldana, Philipp R. , Anderson, Richard C. E. , Baird, Lissa , Bierbrauer, Karin S. , Chern, Joshua J. , Whitehead, William E. , Ellenbogen, Richard G. , Fuchs, Herbert E., Guillaume, Daniel, Hankinson, Todd C. , Iantosca, Mark, Oakes, W. Jerry, Keating, Robert F., Khan, Nickalus R. , Muhlbauer, Michael S., McComb, J. Gordon , Menezes, Arnold H. , Ragheb, John , Smith, Jodi L. , Maher, Cormac O. , Greene, Stephanie , Kelly, Michael P. , O’Neill, Brent R., Krieger, Mark D., Tamber, Mandeep S. , Durham, Susan, Olavarria, Greg, Stone, Scellig , Kaufman, Bruce A., Heuer, Gregory G. , Bauer, David F. , Albert, Gregory W. , Greenfield, Jeffrey P. , Wait, Scott D. , Poppel, Mark D Van, Eskandari, Ramin , Mapstone, Timothy B., Dacey, Ralph G. , Park, Tae Sung, Limbrick, David D. , Torner, James C. , Kelly, Michael P , Shah, Manish N. , Daniels, David J. , Grant, Gerald A. , Selden, Nathan R. W. , Guillaume, Daniel J., Shimony, Joshua S. , Limbrick, David D.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | October 19, 2019 | Volume: 24 | Issue: 5 | Pages: 520-527

10.3171/2019.5.peds18527 | PMID 31419800 Get It

OBJECTIVEScoliosis is frequently a presenting sign of Chiari malformation type I (CM-I) with syrinx. The authors’ goal was to define scoliosis in this population and describe how radiological characteristics of CM-I and syrinx relate to the presence and severity of scoliosis.METHODSA large multicenter retrospective and prospective registry of pediatric patients with CM-I (tonsils ≥ 5 mm below the foramen magnum) and syrinx (≥ 3 mm in axial width) was reviewed for clinical and radiological characteristics of CM-I, syrinx, and scoliosis (coronal curve ≥ 10°).RESULTSBased on available imaging of patients with CM-I and syrinx, 260 of 825 patients (31%) had a clear diagnosis of scoliosis based on radiographs or coronal MRI. Forty-nine patients (5.9%) did not have scoliosis, and in 516 (63%) patients, a clear determination of the presence or absence of scoliosis could not be made. Comparison of patients with and those without a definite scoliosis diagnosis indicated that scoliosis was associated with wider syrinxes (8.7 vs 6.3 mm, OR 1.25, p < 0.001), longer syrinxes (10.3 vs 6.2 levels, OR 1.18, p < 0.001), syrinxes with their rostral extent located in the cervical spine (94% vs 80%, OR 3.91, p = 0.001), and holocord syrinxes (50% vs 16%, OR 5.61, p < 0.001). Multivariable regression analysis revealed syrinx length and the presence of holocord syrinx to be independent predictors of scoliosis in this patient cohort. Scoliosis was not associated with sex, age at CM-I diagnosis, tonsil position, pB–C2 distance (measured perpendicular distance from the ventral dura to a line drawn from the basion to the posterior-inferior aspect of C2), clivoaxial angle, or frontal-occipital horn ratio. Average curve magnitude was 29.9°, and 37.7% of patients had a left thoracic curve. Older age at CM-I or syrinx diagnosis (p < 0.0001) was associated with greater curve magnitude whereas there was no association between syrinx dimensions and curve magnitude.CONCLUSIONSSyrinx characteristics, but not tonsil position, were related to the presence of scoliosis in patients with CM-I, and there was an independent association of syrinx length and holocord syrinx with scoliosis. Further study is needed to evaluate the nature of the relationship between syrinx and scoliosis in patients with CM-I.
Liquid biopsy for diffuse intrinsic pontine glioma: an update
Lu, Victor M. , Power, Erica A. , Zhang, Liang , Power, Erica A , Daniels, David J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | October 19, 2019 | Volume: 24 | Issue: 5 | Pages: 593-600

10.3171/2019.6.peds19259 | PMID 31491754 Get It

Diffuse intrinsic pontine glioma (DIPG), otherwise known as diffuse midline glioma with H3K27M mutation, is a devastating brainstem glioma without a cure. Efforts are currently underway to better optimize molecular diagnoses through biological sampling, which today remains largely limited to surgical biopsy sampling. Surgical intervention is not without its risks, and therefore a preference remains for a less invasive modality that can provide biological information about the tumor. There is emerging evidence to suggest that a liquid biopsy, targeting biofluids such as CSF and blood plasma, presents an attractive alternative for brain tumors in general. In this update, the authors provide a summary of the progress made to date regarding the use of liquid biopsy to diagnose and monitor DIPG, and they also propose future development and applications of this technique moving forward, given its unique histone biology.
Effects of Peptide YY on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men
Izzi‐Engbeaya, Chioma , Jones, Sophie , Crustna, Yoshibye, Machenahalli, Pratibha, Papadopoulou, Deborah , Panayi, Christos, Starikova, Jessica , Eng, Pei Chia , Mills, Edouard , Yang, Lisa, Ratnasabapathy, Risheka , Sykes, Mark, Plumptre, Isabella , Coumbe, Ben, Wing, Victoria C., Pacuszka, Ewa, Bech, Paul, Tharakan, George, Tan, Tricia , Veldhuis, Johannes D. , Abbara, Ali , Comninos, Alexander , Dhillo, Waljit S. , Veldhuis, Johannes, Modi, Manish , Phylactou, Maria , MINNION, JAMES S.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | October 19, 2019 | Volume: 105 | Issue: 3 | Pages: 833-838

10.1210/clinem/dgz103 | PMID 31628465 Get It

Abstract Context Central and peripheral administration of peptide YY (PYY) has potent anorectic effects, and PYY analogs are under development as antiobesity treatments. Recent animal data suggest PYY may also influence the reproductive axis; however the effects of PYY on the human reproductive system are unknown. Objective To investigate the effects of PYY administration on the reproductive axis in healthy young men. Design Single-blind, randomized, placebo-controlled crossover study. Setting Clinical Research Facility, Imperial College Healthcare NHS Trust. Participants Eighteen healthy eugonadal men (mean age 24.1 ± 0.9 years, mean body mass index 22.2 ± 0.4 kg/m2). Intervention Eight-hour intravenous infusion of 0.4 pmol/kg/min PYY3-36 or rate-matched vehicle infusion. Main Outcome Measures Number of luteinizing hormone (LH) pulses, LH, follicle stimulating hormone (FSH), and testosterone levels. Results The number of LH pulses (mean number of LH pulses/8 hours: PYY 4.4 ± 0.3 vs vehicle 4.4 ± 0.4, P &gt; .99), LH area under the curve (AUC) (PYY 1503 ± 79 IU.min/L vs vehicle 1574 ± 86 IU.min/L, P = .36), FSH AUC (PYY 1158 ± 513 IU.min/L vs vehicle 1199 ± 476 IU.min/L, P = .49) and testosterone AUC (PYY 10 485 ± 684 IU.min/L vs vehicle 11 133 ± 803 IU.min/L, P = .24) were similar during PYY and vehicle infusions. Conclusions Acute intravenous infusion of 0.4 pmol/kg/min PYY does not affect the reproductive axis in healthy men.
Direct Oral Anticoagulant Use After Transcatheter Aortic Valve Replacement: A Case Series
Hendricks, Abby K. , Nei, Scott D. , Greason, Kevin L. , Scott, Rachael

Mayo Clinic

Journal of Cardiovascular Pharmacology | October 18, 2019 | Volume: 75 | Issue: 1 | Pages: 41-44

10.1097/fjc.0000000000000755 | PMID 31633585 Get It

Background: Use of an anticoagulant after transcatheter aortic valve replacement (TAVR) has been increasing in practice after noted leaflet thrombosis on dual antiplatelet therapy. As the use of anticoagulation increases so does the number of poor warfarin candidates or warfarin intolerant patients. While direct oral anticoagulant (DOAC) use is increasing for other indications, there is a paucity of data for use after TAVR. The objective of this case series is to add to the available evidence for patients who may require a DOAC after TAVR. Methods: A single-center, retrospective observational case series was conducted including adults 18 years of age and older who received a DOAC after TAVR between November 2008 and June 2018 at Mayo Clinic Hospital—Rochester. All patients were identified as part of the Society of Thoracic Surgeons database. Results: Twenty-one patients were identified as having received a DOAC after TAVR. Median age was 83.5 years (interquartile range 77–87), with 71% males. Within this cohort, 20 patients (95.2%) had an alternative indication for anticoagulation of either atrial fibrillation or atrial flutter. Apixaban was prescribed in 66.7% of patients, followed by rivaroxaban (14.3%), dabigatran (9.5%), and edoxaban (4.8%). No thromboembolic events were reported. Three patients experienced a bleeding event, of which only 2 occurred in the 3 months immediately after TAVR. Conclusions: DOAC therapy after TAVR was generally safe and well tolerated. Taken in context of other retrospective studies, these data suggest that the presence of valvular heart disease, specifically TAVR in this case, should not preclude the use of DOACs.
Potential Association Between Perioperative Fluid Management and Occurrence of Postoperative Ileus
Lovely, Jenna K. , Crippa, Jacopo , Hübner, Martin , Mathis, Kellie L. , Crippa, J , Hübner, Martin , Grass, Fabian , Larson, David W.

Mayo Clinic

Diseases of the Colon & Rectum | October 18, 2019 | Volume: 63 | Issue: 1 | Pages: 68-74

10.1097/dcr.0000000000001522 | PMID 31633601 Get It

BACKGROUND: Postoperative ileus remains an issue after colorectal surgery delaying recovery and increasing the length of hospital stay and costs. OBJECTIVE: The purpose of this study was to analyze the impact of perioperative fluid management on ileus occurrence after colorectal surgery within a fully implemented enhanced recovery pathway. DESIGN: This was a retrospective cohort study of a prospectively maintained institutional database. SETTINGS: The study was conducted at a tertiary academic facility with fully implemented standardized enhanced recovery pathway over the entire study period. PATIENTS: All of the consecutive elective major colorectal resections for benign or malign indications between 2011 and 2016 were included. MAIN OUTCOME MEASURES: Postoperative ileus was defined as the need for nasogastric tube reinsertion. Perioperative fluid management and surgical outcome were compared between patients presenting with ileus and those without. Potential risk factors for ileus were identified through multinomial logistic regression. RESULTS: Postoperative ileus occurred in 377 (9%) of 4205 included patients at day 4 (interquartile range, 2–5 d). Intraoperatively, ileus patients received 3.2 ± 2.6 L of fluids, whereas the remaining patients received 2.5 ± 1.7 L (p < 0.001). Weight gain was 3.8 ± 7.1 kg in ileus patients versus 3.0 ± 6.6 kg (p = 0.272) in the remaining patients at postoperative day 1, 4.4 ± 6.5 kg versus 3.1 ± 7.0 kg (p = 0.028) at postoperative day 2, and 1.8 ± 6.0 kg versus 0.0 ± 6.0 kg at discharge (p = 0.002). The multivariable model including all significant (p < 0.05) demographic, fluid management–related, and surgical parameters retained postoperative day 0 fluids of >3 L (OR = 1.65 (95% CI, 1.13–2.41); p = 0.009), postoperative day 2 weight gain of >2.5 kg (OR = 1.49 (95% CI, 1.01–2.21); p = 0.048), and occurrence of postoperative complications (OR = 2.00 (95% CI, 1.39–2.90); p < 0.001) as independent risk factors for ileus. LIMITATIONS: This study was limited by its retrospective design. Fluid management depends on patient-, disease-, and surgery-related factors and cannot be generalized and extrapolated. CONCLUSIONS: Fluid overload and occurrence of postoperative complications were independent risk factors for postoperative ileus. This calls for action to keep perioperative fluids below suggested thresholds. See Video Abstract at http://links.lww.com/DCR/B54. ASOCIACIÓN POTENCIAL ENTRE EL MANEJO DEL LÍQUIDO PERIOPERATORIO Y EL SUCESO DE ÍLEO POSTOPERATORIO ANTECEDENTES: El íleo postoperatorio sigue siendo un problema después de una cirugía colorrectal que retrasa la recuperación y aumenta la duración de la estancia hospitalaria y los costos. OBJETIVO: Analizar el impacto del manejo del líquido perioperatorio en la incidencia de íleo después de la cirugía colorrectal dentro de una vía de recuperación mejorada totalmente implementada. DISEÑO: Estudio de cohorte retrospectivo de una base de datos institucional mantenida prospectivamente. MARCO: Centro académico terciario con una ruta de recuperación mejorada estandarizada completamente implementada durante todo el período del estudio. PACIENTES: Se incluyeron todas las resecciones colorrectales mayores electivas consecutivas para indicaciones benignas o malignas entre 2011 y 2016. MEDIDAS DE RESULTADOS PRINCIPALES: El íleo postoperatorio se definió como la necesidad de reinserción de la sonda nasogástrica. El manejo del líquido perioperatorio y el resultado quirúrgico se compararon entre los pacientes con íleo y los que no. Los posibles factores de riesgo para el íleo se identificaron mediante regresión logística multinominal. RESULTADOS: El íleo postoperatorio se ocurrió en 377 (9%) de los 4205 pacientes incluidos al cuarto día (RIC 2-5). Intraoperatoriamente, los pacientes con íleo recibieron 3.2 ± 2.6 L de líquidos, mientras que los pacientes restantes recibieron 2.5 ± 1.7 L (p < 0.001). El aumento de peso fue de 3.8 ± 7.1 kg en pacientes con íleo versus 3 ± 6.6 kg (p = 0.272) en los pacientes restantes en el día postoperatorio 1, 4.4 ± 6.5 kg vs. 3.1 ± 7 kg (p = 0.028) en el día postoperatorio 2 y 1.8 ± 6 kg versus a 0 ± 6 kg al tiempo de alta hospitalaria (p = 0.002). El modelo multivariable que incluye todos los parámetros demográficos, del manejo de líquidos y quirúrgicos significativos (p <0.05) mantuvo líquidos del día 0 después de la operación de> 3L (proporción de probabilidad 1.65, intervalo de confianza del 95% 1.13-2.41, p = 0.009), ganancia de peso de > 2.5 kg en el dia postoperatorio 2 (proporción de probabilidad 1.49, 95% intervalo de confianza 1.01-2.21, p = 0.048) y aparición de complicaciones postoperatorias (proporción de probabilidad 2, 95% intervalo de confianza 1.39-2.9, p <0.001) como factores de riesgo independientes para íleo. LIMITACIONES: Diseño retrospectivo. El manejo de líquidos depende de factores relacionados con el paciente, la enfermedad y la cirugía, y no puede generalizarse ni extrapolarse. CONCLUSIONES: La sobrecarga de líquidos y la aparición de complicaciones postoperatorias fueron factores de riesgo independientes para el íleo postoperatorio. Esto requiere medidas para mantener los líquidos perioperatorios por debajo de los umbrales sugeridos. Vea el Video del Resumen en http://links.lww.com/DCR/B54.